

Table 1. The comparison of the demographic and clinical characteristics of the patient groups

		Group 1		Group 2		P
		Mean±SD		Mean±SD		
Age (mean ± SD,years)		63.6±16.3		59.4±11.0		0.244
		N	%	N	%	
Gender	Male	23	76.7%	22	73.3%	0.766
	Female	7	23.3%	8	26.7%	
Comorbidity	No	5	16.7%	7	23.3%	0.519
	Yes	25	83.3%	23	76.7%	
Types of comorbidity	Hypertension	16	53.3%	10	33.3%	0.118
	Diabetes mellitus	12	40.0%	11	36.7%	
	COPD,Asthma	2	6.7%	4	13.3%	
	Congestive heart disease	4	13.3%	3	10.0%	
	Congestive artery disease	7	23.3%	5	16.7%	
	Coronary artery disease	2	6.7%	1	3.3%	
	Chronic renal disease	4	13.3%	1	3.3%	
	Malignite	4	13.3%	5	16.7%	
	Others	1	3.3%	2	6.7%	
Symptoms	Fever	20	66.7%	15	50.0%	0.190
	Cough	22	73.3%	18	60.0%	
	Dyspnea	15	50,0%	15	50,0%	
	Fatigue	25	83.3%	21	70.0%	
	Sore throat	5	16.7%	12	40.0%	
	Sputum	10	33.3%	6	20.0%	
	Headache	5	16.7%	11	36.7%	
	Myalgia	22	73.3%	18	60.0%	
	Nause and diarrhea	5	16.7%	5	16.7%	
	Fever Mean±SD (Min-Max)	38.4±0.7 37-40 (38.5)		37.9±0.7 36.4-39.5 (37.8)		0.010

		Group 1		Group 2		
		n	%	n	%	p
PCR 1	Positive	17	63.0%	21	72.4%	0.449
	Negative	10	37.0%	8	27.6%	
PCR 2	Positive	17	63.0%	15	51.7%	0.396
	Negative	10	37.0%	14	48.3%	
Severity of the disease	Moderate	9	30.0%	12	40.0%	0.002
	Severe	11	36.7%	18	60.0%	

	Very severe	10	33.3%	0	0.0%	
Chest CT	Patchy Opacity	16	53.3%	10	33.3%	0.066
	Cord Shadow	14	46.7%	15	50.0%	
	Consolidation	0	0.0%	1	3.3%	
	Ground glass	0	0.0%	4	13.3%	
Antiviral treatment	Favipavir	11	36.7%	24	80.0%	0.001
	Favipravir+Lopinavir+Ritonavir	3	10.0%	0	0.0%	
	Favipavir+Oseltamivir	9	30.0%	6	20.0%	
	Favipravir+Lopinavir+Ritonavir+Oseltamivir	7	23.3%	0	0.0%	
Plaquenil		29	96.7%	26	86.7%	0.353
Azitro		22	73.3%	24	80.0%	0.542
Steroid		20	69.0%	7	23.3%	<0.001
Anticoagulation		30	100.0%	29	96.7%	1.000

$P < 0.05$ is statistically significant

Tablo 2. The laboratory findings of the patient groups

	Group 1		Group 2		
	Mean±SD	Min-Max (Median)	Mean±SD	Min-Max (Median)	p
IL-6			178.0±172,0	12.2-634 (133.7)	
pO ₂ /FiO ₂ (baseline)	101.4±23.4	49-150 (98)	116.5±30.6	49-167 (116)	0.020
pO ₂ /FiO ₂ (2nd day)	112.1±36,8	67-194 (104)	137.4±30.9	69-173 (138)	0.006
pO ₂ /FiO ₂ (7th day)	147.4±86.6	49-343 (141.5)	239.4±51.3	148-358 (228)	<0.001
D-DİMER (baseline)	4.73±5.97	0.46-30.54 (2.56)	3.82±6.52	0.41-35 (2.29)	0.167
D-DİMER (2nd day)	5.51±5.76	0.83-23 (3.40)	3.97±4.05	0.40-17.14 (2,29)	0.316
D-DİMER (7th day)	6.82±9.32	0.91-35 (3.75)	2.72±2.55	0.50-9 (1.42)	0.015
FERRİTİN (baseline)	1151.7±331.4	459-1500 (1137.5)	1002.5±402.1	197-1500 (995)	0.191
FERRİTİN (2nd day)	1125.0±345.8	534-1500 (1150)	692.5±368.4	178-1500 (561)	<0.001
FERRİTİN (7th day)	966.0±338.1	201-1500 (952)	466.0±363.4	0.1-1500 (345)	<0.001
LDH (baseline)	402.4±133.4	112-743 (373.5)	478.2±237.8	238-1421 (421)	0.255
LDH (2nd day)	505.3±448.6	222-2342 (398.5)	447.8±339.1	169-2066 (384)	0.883
LDH (7th day)	384.4±213.9	138-1133 (320.5)	348.0±131.8	152-780 (335)	0.936
CRP (baseline)	216.4±68.5	99-417 (207.5)	194.5±74.6	24-410 (182.5)	0.241
CRP (2nd day)	182.1±60.4	33.7-289 (181)	45.2±37.1	7.9-195 (30)	<0.001
CRP (7th day)	119.7±89.3	5.2-314 (112)	7.6±5.9	2.4-32 (6.4)	<0.001
PLATELET (baseline)	235.9±118.0	18-606 (214.5)	224.9±94.9	75-455 (198)	0.701
PLATELET (2nd day)	256.4±150.2	19-786 (229.5)	294.6±130.5	76-593 (272)	0.301
PLATELET	283.7±159.2	24-688 (250)	305.5±144.7	64-590 (279.5)	0.599

(7th day)

LENFOSİT (baseline)	543.3±280.8	130-1260 (430)	722.0±336.7	170-1910 (680)	0.016
LENFOSİT (2nd day)	731.0±424.6	200-2250 (690)	1001.4±471.3	180-2080 (980)	0.009
LENFOSİT (7th day)	1016.6±433.1	310-2110 (990)	1370.4±620.3	310-2640 (1275)	0.027
PLR (baseline)	0.49±0.33	0.06-1.55 (0.42)	0.37±0.22	0.11-1.06 (0.31)	0.148
PLR (2nd day)	0.44±0.32	0.01-1.45 (0.36)	0.33±0.14	0.13-0.66 (0.32)	0.214
PLR (7th day)	0.31±0.18	0.02-0.77 (0.30)	0.24±0.11	0.08-0.58 (0.21)	0.129

LDH= Lactate dehydrogenase; CRP= C- reactive protein; PLR= Platelet-to lymphocyte ratio

P<0.05 is statistically significant

